“Cepacia syndrome” associated with <i>Burkholderia cepacia</i> (Genomovar I) infection in an adolescent with cystic fibrosis

Nash, Edward F.; Thomas, Ajit; Whitmill, Richard; Rashid, R.; Barker, Bethan; Rayner, Rosie J.; Whitehouse, J.L.; Honeybourne, D.

doi:10.1002/ppul.21404

Cited by 11 publications

(9 citation statements)

References 15 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bcc are also opportunistic human pathogens that cause lung infections in immune-compromised individuals, including cystic fibrosis (CF) patients [ 19 ]. In one-third of infected individuals, it causes the “cepacia syndrome”—a form of septic shock, which involves the lungs essentially shutting down, resulting in fatality [ 20 , 21 , 22 ]. Bcc bacteria have proven to be very resilient and incredibly difficult to combat as they are resistant to almost all known antimicrobial agents and can survive under the most extreme conditions [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial Activity of Monoramnholipids Produced by Bacterial Strains Isolated from the Ross Sea (Antarctica)

et al. 2016

View full text Add to dashboard Cite

Microorganisms living in extreme environments represent a huge reservoir of novel antimicrobial compounds and possibly of novel chemical families. Antarctica is one of the most extraordinary places on Earth and exhibits many distinctive features. Antarctic microorganisms are well known producers of valuable secondary metabolites. Specifically, several Antarctic strains have been reported to inhibit opportunistic human pathogens strains belonging to Burkholderia cepacia complex (Bcc). Herein, we applied a biodiscovery pipeline for the identification of anti-Bcc compounds. Antarctic sub-sea sediments were collected from the Ross Sea, and used to isolate 25 microorganisms, which were phylogenetically affiliated to three bacterial genera (Psychrobacter, Arthrobacter, and Pseudomonas) via sequencing and analysis of 16S rRNA genes. They were then subjected to a primary cell-based screening to determine their bioactivity against Bcc strains. Positive isolates were used to produce crude extracts from microbial spent culture media, to perform the secondary screening. Strain Pseudomonas BNT1 was then selected for bioassay-guided purification employing SPE and HPLC. Finally, LC-MS and NMR structurally resolved the purified bioactive compounds. With this strategy, we achieved the isolation of three rhamnolipids, two of which were new, endowed with high (MIC < 1 μg/mL) and unreported antimicrobial activity against Bcc strains.

show abstract

Section: Introductionmentioning

confidence: 99%

Antimicrobial Activity of Monoramnholipids Produced by Bacterial Strains Isolated from the Ross Sea (Antarctica)

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In addition to these experimental data, the apparent aggressiveness of BCC bacteria in CF is also consistent with BCC bacteria deploying differential pathogenic mechanisms during chronic infections. Most notable is the well described capacity for BCC to cause a typically fatal invasive necrotizing pneumonia known as ‘cepacia syndrome’, which has commonly been associated with B. cenocepacia but is also known to occur in other species including B. multivorans and B. dolosa [19]–[21]. Invasive disease is rarely, if ever, seen in P. aeruginosa infections in CF.…”

Section: Introductionmentioning

confidence: 99%

Swimming Motility in a Longitudinal Collection of Clinical Isolates of Burkholderia cepacia Complex Bacteria from People with Cystic Fibrosis

Zlosnik

Mori

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Chronic bacterial lung infections in cystic fibrosis (CF) are the leading cause of morbidity and mortality. While a range of bacteria are known to be capable of establishing residence in the CF lung, only a small number have a clearly established link to deteriorating clinical status. The two bacteria with the clearest roles in CF lung disease are Pseudomonas aeruginosa and bacteria belonging to the Burkholderia cepacia complex (BCC). A number of common adaptations by P. aeruginosa strains to chronic lung infection in CF have been well described. Typically, initial isolates of P. aeruginosa are nonmucoid and display a range of putative virulence determinants. Upon establishment of chronic infection, subsequent isolates ultimately show a reduction in putative virulence determinants, including swimming motility, along with an acquisition of the mucoid phenotype and increased levels of antimicrobial resistance. Infections by BCC are marked by an unpredictable, but typically worse, clinical outcome. However, in contrast to P. aeruginosa infections in CF, studies describing adaptive changes in BCC bacterial phenotype during chronic lung infections are far more limited. To further enhance our understanding of chronic lung infections by BCC bacteria in CF, we assessed the swimming motility phenotype in 551 isolates of BCC bacteria from cystic fibrosis (CF) lung infections between 1981 and 2007. These data suggest that swimming motility is not typically lost by BCC during chronic infection, unlike as seen in P. aeruginosa infections. Furthermore, while we observed a statistically significant link between mucoidy and motility, we did not detect any link between motility phenotype and clinical outcome. These studies highlight the need for further work to understand the adaptive changes of BCC bacteria during chronic infection in the CF lung.

show abstract

“…The reasons for these disparate outcomes are not understood; thus accurate prognoses for CF patients infected with BCC are extremely difficult to define. While a number of different BCC species have been associated with “cepacia syndrome” (Zahariadis et al, 2003 ; Nash et al, 2011 ), historically infections caused by Burkholderia cenocepacia have been associated with a higher risk of developing “cepacia syndrome” than the other species (Mahenthiralingam et al, 2001 ; Jones et al, 2004 ). A further complication of infection with B. cenocepacia appears to be a higher risk of death following lung transplantation, often as a result of sepsis (Alexander et al, 2008 ; De Soyza et al, 2010 ).…”

Section: Introductionmentioning

confidence: 99%

Serum Susceptibility in Clinical Isolates of Burkholderia Cepacia Complex Bacteria: Development of a Growth-Based Assay for High Throughput Determination

Zlosnik

Gunaratnam

Speert

2012

Front. Cell. Inf. Microbio.

View full text Add to dashboard Cite

Burkholderia cepacia complex (BCC) bacteria can cause devastating chronic infections in people with cystic fibrosis. Of particular concern is “cepacia syndrome,” a rapidly progressive and usually fatal decline in health, characterized by a necrotizing bacteremic pneumonia. An important component of defense against bloodstream infections is the bactericidal action of serum. Traditional methods to determine the capacity of bacterial isolates to resist the bactericidal effects of serum are relatively low-throughput viability assays. In this study, we developed a novel growth-based assay for serum susceptibility, which allows for high throughput analysis. We applied this assay to a range of clinical isolates of BCC as well as isolates comprising the BCC experimental strain panel. Our data demonstrate that isolates from all species of BCC examined can possess serum resistant or serum sensitive/intermediate phenotypes. Of particular clinical significance, we also found no direct link between the last saved pulmonary isolate from patients who subsequently developed “cepacia syndrome” and their capacity to resist the inhibitory effects of human serum, suggesting serum resistance cannot be used as a marker of an isolate’s capacity to escape from the lung and cause bacteremia.

show abstract

“Cepacia syndrome” associated with Burkholderia cepacia (Genomovar I) infection in an adolescent with cystic fibrosis

Cited by 11 publications

References 15 publications

Antimicrobial Activity of Monoramnholipids Produced by Bacterial Strains Isolated from the Ross Sea (Antarctica)

Antimicrobial Activity of Monoramnholipids Produced by Bacterial Strains Isolated from the Ross Sea (Antarctica)

Swimming Motility in a Longitudinal Collection of Clinical Isolates of Burkholderia cepacia Complex Bacteria from People with Cystic Fibrosis

Serum Susceptibility in Clinical Isolates of Burkholderia Cepacia Complex Bacteria: Development of a Growth-Based Assay for High Throughput Determination

Contact Info

Product

Resources

About